Feeds:
Posts
Comments

Posts Tagged ‘Forest Labs’

COMING UP SOON: BDI’s Social Communications and Healthcare half-day gathering. NYC, May 11 – all details here. I will be leading a roundtable. Use discount code IMPACT for $155 registration rate.

*****

TODAY’S NEWS

Allergan – Rolling high-stakes legal dice re: Botox. Here and here.

Novo’s Victoza: nice results in comparison with Merck‘s Januvia. Plus, an experimental Januvia competitor gets dropped by Forest Labs.

Experimental once-a-day malaria drug looking really good – An experimental once-a-day malaria drug worked as well at treating the mosquito-borne illness as Novartis AG’s twice-daily pill Coartem, according to a study published today in the journal Lancetmore

RECOMMENDED

Account Management Training – Need to make your account managers more effective? Creative and successful programs are available from Impactiviti’s partner network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Surround Yourself with Smart People.

JUST FOR FUN

Serene Sunrises. 40. A visual treat.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Advertisements

Read Full Post »

*****

Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!

For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.

TODAY’S NEWS

In Celgene‘s pipeline – a promising oral RA (Rheumatoid Arthritis) treatment – Celgene Corp. believes sales of lead development candidate Apremilast will be $2 billion to $3 billion a year in psoriasis and psoriatic arthritis. The drug, which would compete with some of the world’s biggest selling therapies, is expected to enter late-stage trials this year and could be launched in 2014 or 2015, the company said. The projection came during the Summit, N.J., drug maker’s research and development presentation in New York Thursdaymore But, not such good news about low-dose aspirin as a RA preventative.

Oh, by the way – there were a few suicides, too. How not to get approval for Daxas (Forest Labs).

The arguments begin the Novartis discrimination lawsuit. How many isolated incidents indicate a systemic problem? This one’s going to get sticky…

Letting Go. A challenge to think differently.

RECOMMENDED

Diversity/Ethics training– We can recommend best-in-class partners and programs for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

“Compulsive Generosity” due to Parkinson’s Rx – an embezzler gets off with an imaginative “the drug made me do it” plea. Ludicrous.

JUST FOR FUN

The Enlightened Stupid Marketer. 3 1/2 minutes of fun with Kevin Nalts.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Keep some Lexapro around for strokes. Forest Laboratories Inc.’s antidepressant Lexapro may help stroke patients recover some of their mental skills, a study said. Patients who took Lexapro recovered more of their visual and verbal memory after 12 months of treatment than those given a placebo or those who underwent therapy without drugs, researchers reported todaymore

Will there be a new dementia treatment coming? – Doctors may learn next month that Dimebon, a 27-year-old hay fever treatment and one of the most mysterious compounds yet tried to fight dementia, is poised to become their newest and perhaps best weapon against Alzheimer’smore

What will the sales rep of the future look like?

Cialis strategy – just charge more!

RECOMMENDED

Technology – How do you make sense of technology platforms for learning management, on-line assessment, social media, simulations, virtual worlds, and more? We can help – we stay right on top of that stuff. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Impactiviti‘s new, searchable Pharma Job Board (powered by SimplyHired). Check it out!

JUST FOR FUN

Having a bad day? This little video clip will cure it! Bad Day Cure.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

FDA panel to Forest on new use for heart drug: thumbs down – Federal health advisers on Monday unanimously rejected a new use of Forest Laboratories’ hypertension drug for patients at risk of heart failure. The Food and Drug Administration’s outside panel of heart specialists voted 8-0 against approving Bystolic to prevent death or hospitalization caused by heart failure, according to an agency spokeswoman….more

Withdrawal rates, Oxycontin, and selective publication of details. Sigh, Purdue.

Vivus’ new erectile dysfunction drug: fast results – Vivus Inc. on Monday reported positive test results for its erectile dysfunctional drug candidate avanafil, saying most men who took the drug were able to have sex within 15 minutesmore

Vertex lost less than $650 million in 2009. Well, that’s a relief!

The Medicines Company cutting 10% of workforce. Ouch.

RECOMMENDED

Virtual Preceptorships. Great eLearning+Clinical understanding+Pharma training expertise. Our vendor/partners have that. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

$3M CME grant with NO strings attached? Wow (Pfizer-Stanford)!

JUST FOR FUN

Obnoxious guitar design. Really. Obnoxious.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »